Neratinib/T-DM1 Combo Shows Promise in HER2-Positive Breast Cancer
Pharma & biotech2018-06-18
2 Views
The combination of neratinib and T-DM1 induced an overall response rate of 60% in previously-treated women with HER2-positive metastatic breast cancer.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Breaking News: Crown Equity Holdings, Inc. Announces Letter of Intent with BioHarvest Naturals Corp.
